HIV

New recommendations urge health care providers to offer pre-exposure prophylaxis (PrEP) to individuals at high risk of HIV.

Antiretroviral drug treatment was not found to be a cause of the higher prevalence of hypertension in persons infected with HIV.

Cellular proliferation predominantly drives HIV persistence on antiretroviral therapy, according to a new study.

Top news of the day from across the health care landscape.

Hispanic adults in the US who are infected with human immunodeficiency virus face a greater risk of cancers caused by human papillomavirus (HPV) than Hispanics in the general public.

The FDA has approved lamivudine and tenofovir disoproxil fumarate (Temixys, Celltrion) tablets, 300 mg/300 mg in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients weighing at least 35 kg.

Research on nonalcoholic fatty liver disease (NAFLD) in persons infected with HIV revealed a prevalence of the condition of about 40%, suggesting the condition may be an underappreciated comorbidity in this population.

Sofosbuvir, velpatasvir, and voxilaprevir successful in patients with hepatitis C virus infection, with and without HIV co-infection, including those with prior noncompletion of treatment or poor adherence to direct-acting antiviral drug regimens.

Stigma may cause undiagnosed individuals with HIV to go unidentified and fail to get quality care and treatment.

Several large investigations have demonstrated the considerable efficacy of TDF/FTC taken daily or intermittently, reducing the risk of HIV acquisition by more than 95% in high-risk individuals.

A total of 85% of AMBER study participants (308/362) achieved virologic suppression (viral load

Preliminary data show that treatment with anti-PD-1 inhibitors may be feasible in patients with HIV and cancer.

Hepatitis C virus found to increase mortality in individuals coinfected with HIV, however, treatment with direct-acting antivirals may reduce harm.

Top news of the week from Specialty Pharmacy Times.

New analysis examines the role of the HIV/AIDS epidemic in cancer survival rates among adolescents and young adults.

Coinfection with HIV and tuberculosis may affect drug-related adverse events, hospital readmissions, and treatment duration.

ViiV Healthcare has submitted a New Drug Application (NDA) for its single-tablet, 2-drug regimen of dolutegravir (DTG) and lamivudine (3TC) for the treatment of HIV-1 infection.

Dolutegravir plus lamivudine showed non-inferiority to a 3-drug, first-line regimen in treating HIV infection.

The first study to evaluate population-level roll-out of pre-exposure prophylaxis (PrEP) for HIV in men who have sex with men has demonstrated rapid decline of new HIV infections.

A combination of next generation broadly neutralizing antibodies might be able to achieve long-term viral suppression of HIV without the need for a daily antiretroviral pill, according to recently published research.

Provider-centric stigma reduction interventions can help reduce stigmatizing behaviors towards patients with HIV and potentially improve care, according to a new systematic review from the CDC.

Report analyzes HIV-related stigma among health care providers and the potential impact on quality of patient care.

Broadly neutralizing antibodies have one key advantage over antiretroviral therapy: they have a longer half-life and thus don’t require the daily, lifelong dosing regimen currently required of ART users.

Researchers investigated the impact of individual types of human papilloma virus on HIV acquisition.

A new combination treatment that targets the latent reservoir of HIV may be a potential effective therapeutic strategy.